Compare BZFD & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZFD | LGVN |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | 507 | N/A |
| Industry | Movies/Entertainment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 34.0M |
| IPO Year | N/A | 2021 |
| Metric | BZFD | LGVN |
|---|---|---|
| Price | $1.46 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 7.2M | 379.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $108.06 | $10.81 |
| P/E Ratio | $292.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.48 |
| 52 Week High | $2.68 | $1.80 |
| Indicator | BZFD | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 49.34 |
| Support Level | $0.74 | $0.74 |
| Resistance Level | $1.77 | $0.86 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 23.44 | 78.25 |
BuzzFeed Inc is a digital media company across pop culture, entertainment, shopping, food, and news, its brands drive conversation and inspire what audiences watch, read, and buy now and into the future. Its iconic, globally-loved brands include BuzzFeed, HuffPost, and Tasty. The company generates revenue from advertising, content, commerce, and other sources.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.